By Karen Roman
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) said IP Australia approved a patent application for an activator targeting autoimmune diseases.
This should open the path to approvals in other countries, Conduit said in a statement.
“With up to 20 years of patent protection and drug substance classification secured, this patent not only validates the robustness of our internal R&D capabilities but also significantly strengthen our position for future out-licensing opportunities,” said Dr. David Tapolczay, Conduit’s CEO.
Contact:
Editor@executives-edge.com
